港股異動 | 金山軟件漲逾4% 金山辦公提交科創板註冊
格隆匯10月8日丨金山軟件(3888.HK)現報18.02港元,漲4.65%,暫成交9117萬港元,最新總市值247.4億港元。上交所官網顯示,金山軟件分拆金山辦公已提交科創板註冊,更新日期為10月6日,金山辦公擬融資20.5億元。繼小米集團和金山軟件之後,雷軍或將迎來自己實際控制的第三家上市公司。據悉,金山辦公是一家辦公軟件和服務提供商,產品主要包括WPSOffice辦公軟件和金山詞霸等,主要從事WPSOffice產品及服務的設計研發及銷售推廣。此外據悉,南下資金近期持續流入金軟,港股通累計持倉比例自7月底的15.87%逐步升至8月底的17.69%,及至9月底的22.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.